New HIV-inhibiting protein identified

Scientists have identified a new HIV-suppressing protein in the blood of people infected with the virus. In laboratory studies, the protein, called CXCL4 or PF-4, binds to HIV such that it cannot attach to or enter a human cell. The research was led by Paolo Lusso, M.D., Ph.D., chief of the Section of Viral Pathogenesis in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH.

CXCL4 belongs to a family of called chemokines that help regulate the movement of around the body. In the mid-1990s, four chemokines—three discovered by Dr. Lusso, Robert Gallo, M.D., and their colleagues—were found in laboratory experiments to function as HIV inhibitors. These chemokines as well as CXCL4 may regulate the level of virus replication in infected individuals and thus the pace at which HIV disease progresses.

According to Dr. Lusso, the site where CXCL4 binds to the outer coat of HIV seems to be different from other known vulnerable sites targeted by HIV-blocking antibodies and drugs. His team is working with scientists at the NIAID Vaccine Research Center to define the atomic-level crystal structure of this binding site, which potentially may play a role in the future development of HIV treatments or vaccines.

CXCL4 differs from the other four major HIV-suppressive chemokines in several respects. The other four chemokines inhibit HIV infection by binding to either one of two cell receptors—called CCR5 and CXCR4—used by the virus to attach to and enter immune cells, whereas CXCL4 binds directly to the outer surface of the . While the other chemokines bind to forms of HIV that use either the CCR5 or the CXCR4 receptor, CXCL4 can bind to and block infection by a wide variety of HIV strains, no matter what their receptor specificity. Finally, while the other chemokines are made primarily by immune cells, CXCL4 is made by platelets, the blood cells involved in clotting.

Dr. Lusso and his colleagues are pursuing further research to better understand CXCL4's role in disease and to determine whether the chemokine has a protective effect not only in laboratory studies, but also in people.

More information: DJ Auerbach et al., Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor. PNAS DOI: 10.1073/pnas.1207314109 (2012).

Related Stories

Scientists identify new cellular receptor for HIV

Feb 10, 2008

A cellular protein that helps guide immune cells to the gut has been newly identified as a target of HIV when the virus begins its assault on the body's immune system, according to researchers from the National Institute ...

Scientists reactivate immune cells exhausted by chronic HIV

Jun 03, 2011

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have demonstrated why certain immune cells chronically exposed to HIV shut down, and how they can ...

Scientists find another key to HIV success

Mar 22, 2006

Weill Cornell Medical College scientists say they've determined a protein produced by HIV infected cells prevents immune B cells from producing antibodies.

Recommended for you

Intimacy a strong motivator for PrEP HIV prevention

Aug 19, 2014

Men in steady same-sex relationships where both partners are HIV negative will often forgo condoms out of a desire to preserve intimacy, even if they also have sex outside the relationship. But the risk of ...

UNL sociologist studies HIV spread in rural Puerto Rico

Aug 14, 2014

Puerto Rico has one of the highest HIV rates in the United States, primarily from drug users sharing needles. To help prevent HIV infections, a University of Nebraska-Lincoln sociologist is using his expertise ...

User comments